Survival Benefit of FLT3 Inhibitor Maintenance After Allo-HSCT in FLT3-ITD AML: A Systematic Review and Reconstructed Individual Patient Data Meta-Analysis of Randomized Controlled Trials (SOHO 2026) - Sep 1, 2026 - Abstract #AML-1587; Location: LEVEL 3, HALL B3; " PubMed, Embase, and Scopus were systematically searched from database inception through April 2026 for randomized phase 2/3 trials evaluating FLT3 inhibitor maintenance (sorafenib, midostaurin, or gilteritinib) vs standard care alone in adults with FLT3-ITD AML in complete remission following allo-HSCT. FLT3 inhibitor maintenance after allo-HSCT was associated with significantly improved RFS and OS in adults with FLT3-ITD AML. These findings support the incorporation of posttransplant FLT3 inhibitor maintenance into treatment strategies in eligible patients. Further prospective studies are warranted to define optimal agent selection, treatment duration, and minimal residual disease-guided approaches."
Retrospective data • Review • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology
|
|
Sahithi MC Paramkusam MBBS 1; Abhinav V Paramkusam MD 2; Mehak Dang MD 3; Sravani Bhavanam MD 4; Sameer Kumar Majety MBBS 5; Sushmitha Venkata Annadatha MD 2; Fahad Alabbas MD 6
|